Radioligand therapy is held back less by the science than by the system that delivers it. Theranostix turns the European theranostics delivery picture into intelligence companies can act on — independently, and from the inside of the specialty.
Theranostix grew out of Nucleascope — the independent European nuclear-medicine portal used by physicians, technologists, radiopharmacists and physicists across nine countries and six languages. That community, and the structured data behind it, revealed something pharma couldn't easily see: which centres are genuinely ready to deliver therapy.
Theranostix packages that ground-truth, plus the trial and pipeline landscape, into a commercial intelligence service — kept strictly separate from the free clinician portal so both stay credible.
Specialist in nuclear medicine, practising for over 30 years across Belgium and France, trained at the Université libre de Bruxelles. Deeply involved in PET-CT in oncology and cardiology, and co-founder of Esperity — with a long track record of building digital tools for clinical research and patient support (including MyClinicalTrial / cancertrials.be).
Theranostix is prepared and led by Dr le Beau de Hemricourt, combining clinical authority with a commercial intelligence mission.
Founder · Nuclear-medicine specialist · Co-founder, Esperity
No patient data. No pay-to-rank. Sponsored content always labelled. Public-source provenance. It's what makes the intelligence worth trusting.
Read the independence charter